May 22, 2025 05:00 PM EDT

Roche confirms overall survival benefit for PI3K inhibitor in breast cancer

Max Gelman

Senior Editor

The final overall survival results are in for Roche’s PI3K inhibitor, known as Itovebi, in certain forms of breast cancer. And they bode well for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

House passes Trump tax bill with PBM and orphan drug reforms included

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?